5-methoxy-1-2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4-7-dione and Neoplasms

5-methoxy-1-2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4-7-dione has been researched along with Neoplasms* in 2 studies

Reviews

1 review(s) available for 5-methoxy-1-2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4-7-dione and Neoplasms

ArticleYear
NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
    Journal of medicinal chemistry, 2018, 08-23, Volume: 61, Issue:16

    NAD(P)H:quinone oxidoreductase 1 (NQO1) is a two-electron reductase responsible for detoxification of quinones and also bioactivation of certain quinones. It is abnormally overexpressed in many tumors and intimately linked with multiple carcinogenic processes. NQO1 is considered to be a cancer-specific target for therapy but currently available NQO1 inhibitors have not yet led to chemotherapeutic success. Utilization of NOQ1's ability to bioactivate chemotherapeutic quinones, however, has emerged as a promising selective anticancer therapy. On the basis of the different levels of NQO1 between cancer and normal cells, the catalytic property of NQO1 has recently been exploited to develop effective probes for cancer detection. This article summarizes the most significant advances concerning the discovery and development of NQO1 inhibitors, NQO1-directed chemotherapeutic quinones, and NQO1-activated optical probes, along with the prospects and potential obstacles in this research area.

    Topics: Antineoplastic Agents; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Quinones

2018

Other Studies

1 other study(ies) available for 5-methoxy-1-2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4-7-dione and Neoplasms

ArticleYear
Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent.
    Toxicology and applied pharmacology, 2014, Dec-15, Volume: 281, Issue:3

    Beta-lapachone (beta-Lp) derived from the Lapacho tree is a potentially novel anticancer agent currently under clinical trials. Previous studies suggested that redox activation of beta-Lp catalyzed by. quinone oxidoreductase 1 (NQO1) accounted for its killing of cancer cells. However, the exact mechanisms of this effect remain largely unknown. Using chemiluminescence and electron paramagnetic resonance (EPR) spin-trapping techniques, this study for the first time demonstrated the real-time formation of ROS in the redox activation of beta-lapachone from cancer cells mediated by mitochondria and NQO1 in melanoma B16-F10 and hepatocellular carcinoma HepG2 cancer cells. ES936, a highly selective NQO1 inhibitor, and rotenone, a selective inhibitor of mitochondrial electron transport chain (METC) complex I were found to significantly block beta-Lp meditated redox activation in B16-F10 cells. In HepG2 cells ES936 inhibited beta-Lp-mediated oxygen radical formation by ~80% while rotenone exerted no significant effect. These results revealed the differential contribution of METC and NQO1 to beta-lapachone-induced ROS formation and cancer cell killing. In melanoma B16-F10 cells that do not express high NQO1 activity, both NOQ1 and METC play a critical role in beta-Lp redox activation. In contrast, in hepatocellular carcinoma HepG2 cells expressing extremely high NQO1 activity, redox activation of beta-Lp is primarily mediated by NQO1 (METC plays a minor role). These findings will contribute to our understanding of how cancer cells are selectively killed by beta-lapachone and increase our ability to devise strategies to enhance the anticancer efficacy of this potentially novel drug while minimizing its possible adverse effects on normal cells.

    Topics: Activation, Metabolic; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Electron Transport Complex I; Enzyme Inhibitors; Humans; Indolequinones; Mice; Mitochondria; NAD(P)H Dehydrogenase (Quinone); Naphthoquinones; Neoplasm Proteins; Neoplasms; Oxidation-Reduction; Prodrugs; Reactive Oxygen Species; Reverse Transcriptase Inhibitors; Rotenone

2014